Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial

The Lancet

Volumn 389, Issue 10076, 2017, Pages 1312-1322

  Nijssen, Estelle C ^a   Rennenberg, Roger J ^a   Nelemans, Patty J ^a   Essers, Brigitte A ^a   Janssen, Marga M ^a   Vermeeren, Marja A ^a   Ommen, Vincent van ^a   Wildberger, Joachim E ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; IOPROMIDE; SODIUM CHLORIDE; CONTRAST MEDIUM; IOHEXOL;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DRUG EXPOSURE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FLUID THERAPY; HEART FAILURE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYDRATION; HYPERNATREMIA; HYPONATREMIA; INCIDENCE; INTENTION TO TREAT ANALYSIS; KIDNEY FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; POPULATION; PRACTICE GUIDELINE; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COST; ECONOMICS; GLOMERULUS FILTRATION RATE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; PROCEDURES; TREATMENT OUTCOME;

AGED; CONTRAST MEDIA; COSTS AND COST ANALYSIS; CREATININE; FEMALE; FLUID THERAPY; GLOMERULAR FILTRATION RATE; HUMANS; INFUSIONS, INTRAVENOUS; IOHEXOL; KIDNEY DISEASES; MALE; PROSPECTIVE STUDIES; RISK FACTORS; SODIUM CHLORIDE; TREATMENT OUTCOME;

EID: 85013675000     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30057-0     Document Type: Article

References (30)

1. 1 Nash, K, Hafeez, A, Hou, S, Hospital-acquired renal insufficiency. Am J Kidney Dis 39 (2002), 930–936.
2. 2 Bartels, ED, Brun, GC, Gammeltoft, A, Gjørup, PA, Acute anuria following intravenous pyelography in a patient with myelomatosis. Acta Med Scand 150 (1954), 297–302.
3. 3 Hou, SH, Bushinsky, DA, Wish, JB, Cohan, JJ, Harrington, JT, Hospital acquired renal insufficiency: a prospective study. Am J Med 74 (1983), 234–248.
4. 4 McCullough, P, Contrast-induced acute kidney injury. JACC 51 (2008), 1419–1428.
5. 5 Kidney Disease Improving Global Outcomes. KDIGO clinical practice guideline for acute kidney injury. http://kdigo.org/home/guidelines/ (accessed Aug 22, 2016).
6. 6 LaBounty, TM, Shah, M, Raman, SV, Lin, FY, Berman, DS, Min, JK, Within-hospital and 30-day outcomes in 10 7994 patients undergoing invasive coronary angiography with different low-osmolar iodinated contrast media. Am J Cardiol 109 (2012), 1594–1599.
7. 7 Katzberg, RW, Newhouse, JH, Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe?. Radiology 256 (2010), 21–28.
8. 8 James, MT, Samuel, SM, Manning, MA, et al. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis. Circ Cardiovasc Interv 6 (2013), 37–43.
9. 9 European Society of Urogenital Radiology. ESUR guidelines on contrast media, version 9.0. http://www.esur.org/esur-guidelines/, September 2014 (accessed Aug 22, 2016).
10. 10 Veligheids Management Systeem. VMS veiligheidsprogramma: voorkomen van nierinsufficiëntie bij intravasculair gebruik van jodiumhoudende contrastmiddelen. http://www.vmszorg.nl/themas/nierinsufficientie, September, 2009 (accessed Aug 22, 2016).
11. 11 Committee on Drugs and Contrast Media, American College of Radiology (ACR). Manual on contrast media, version 10.2. http://www.acr.org/quality-safety/resources/contrast-manual (accessed Aug 22, 2016).
12. 12 NICE Guidelines: 2. Acute kidney injury: prevention, detection and management of acute kidney injury up to the point of renal replacement therapy. https://www.nice.org.uk/guidance/published?type=csg,cg,mpg,ph,sg,sc, August, 2013 (accessed Aug 22, 2016).
13. 13 Christiansen, C, X-ray contrast media: an overview. Toxicology 209 (2005), 185–187.
14. 14 Jha, V, Garcia-Garcia, G, Iseki, K, et al. Chronic kidney disease: global dimension and perspectives. Lancet 382 (2013), 260–272.
15. 15 Stacul, F, van der Molen, AJ, Reimer, P, et al. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 21 (2011), 2527–2541.
16. 16 Thomsen, HS, Morcos, SK, Barrett, BJ, Contrast-induced Nephropathy: the wheel has turned 360 degrees. Acta Radiol 49 (2008), 646–657.
17. 17 Rudnick, MR, Goldfarb, S, Tumlin, JA, Contrast-induced nephropathy: is the picture any clearer?. Clin J Am Soc Nephrol 3 (2008), 261–262.
18. 18 Bellomo, R, Kellum, JA, Ronco, C, Acute kidney injury. Lancet 380 (2012), 756–766.
19. 19 Hilton, AK, Pellegrino, VA, Scheinkestel, CD, Avoiding common problems associated with intravenous fluid therapy. Med J Aust 189 (2008), 509–513.
20. 20 Prowle, J, Echeverri, J, Ligabo, E, Ronco, C, Bellomo, R, Fluid balance and acute kidney injury. Nat Rev Nephrol 6 (2010), 107–115.
21. 21 Balemans, CE, Reichert, LJ, van Schelven, BI, van den Brand, JA, Wetzels, JF, Epidemiology of contrast material–induced nephropathy in the era of hydration. Radiology 263 (2012), 706–713.
22. 22 Pocock, SJ, Simon, R, Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31 (1975), 102–115.
23. 23 Morcos, SK, Thomsen, HS, Webb, JAW, et al. Contrast-media-induced nephrotoxicity: a consensus report. Eur Radiol 9 (1999), 1602–1613.
24. 24 Hakkaart-van Roijen, L, Van der Linden, N, Bouwmans, CAM, Kanters, TA, Tan, SS, Kostenhandleiding. Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. Zorginstituut Nederland. Geactualiseerde versie 2015. https://www.zorginstituutnederland.nl/publicaties/publicatie/2016/02/29/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg (accessed Nov 4, 2016).
25. 25 Brück, K, Stel, VS, Gambaro, G, et al. CKD prevalence varies across the European general population. J Am Soc Nephrol 27 (2016), 2135–2147.
26. 26 Nierstichting. Feiten en cijfers over nierziekten. https://www.nierstichting.nl/nieren/feiten-en-cijfers (accessed Dec 21, 2016).
27. 27 Jurado-Román, A, Hernández-Hernández, F, García-Tejada, J, et al. Role of hydration in contrast-induced nephropathy in patients who underwent primary percutaneous coronary intervention. Am J Cardiol 115 (2015), 1174–1178.
28. 28 Luo, Y, Wang, X, Ye, Z, et al. Remedial hydration reduces the incidence of contrast-induced nephropathy and short-term adverse events in patients with ST-segment elevation myocardial infarction: a single-center, randomized trial. Intern Med 53 (2014), 2265–2272.
29. 29 Kooiman, J, Sijpkens, YW, van Buren, M, et al. Randomised trial of no hydration vs sodium bicarbonate hydration in patients with chronic kidney disease undergoing acute computed tomography-pulmonary angiography. J Thromb Haem 12 (2014), 1658–1666.
30. 30 Porter, G, Experimental contrast-associated nephropathy and its clinical implications. Am J Cardiol 66 (1990), 18F–22F.